Antiviral Drugs Market

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview of Antiviral Drugs
3.2. Types of Viruses and Viral Diseases
3.3. Mechanism of Action of Antiviral Drugs
3.4. Characteristics of Antiviral Drugs
3.5. Advantages of Antiviral Drugs
3.6. Challenges Associated with Development of Antiviral Drugs
3.7. Key Facts and Future Perspectives of Antiviral Drugs

4. MARKET LANDSCAPE: APPROVED ANTIVIRAL DRUGS
4.1. Approved Antiviral Drugs: Overall Market Landscape
4.1.1. Analysis by Year of Approval
4.1.2. Analysis by Type of Dosage Form
4.1.3. Analysis by Type of Molecule
4.1.4. Analysis by Type of Target Virus
4.1.5. Analysis by Route of Administration
4.1.6. Analysis by Dosing Frequency
4.1.7. Analysis by Target Indication
4.1.8. Analysis by Mechanism of Action

4.2. Approved Antiviral Drugs: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geography (Region-wise)
4.2.4. Analysis by Geography (Country-wise)
4.2.5. Most Active Players: Analysis by Number of Approved Drugs

5. MARKET LANDSCAPE: CLINICAL ANTIVIRAL DRUGS
5.1. Clinical-stage Antiviral Drugs: Overall Market Landscape
5.1.1. Analysis by Phase of Development
5.1.2. Analysis by Type of Molecule
5.1.3. Analysis by Phase of Development and Type of Molecule
5.1.4. Analysis by Type of Dosage Form
5.1.5. Analysis by Route of Administration
5.1.6. Analysis by Target Indication
5.1.7. Analysis by Phase of Development and Target Indication
5.1.8. Analysis by Type of Developer
5.1.9. Analysis by Type of Therapy
5.1.10. Analysis by Target Patient Segment
5.1.11. Analysis by Mechanism of Action
5.1.12. Analysis by Type of Target Virus
5.1.13. Analysis by Number of Doses

5.2. Clinical-Stage Antiviral Drugs: Developer Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Geography (Region-wise)
5.2.4. Analysis by Geography (Country-wise)
5.2.5. Analysis by Company Size and Location of Headquarters
5.2.6. Most Active Players: Analysis by Number of Clinical-Stage Drugs

6. COMPANY PROFILES
6.1. AbbVie
6.1.1. Company Overview
6.1.2. Key Executives
6.1.3. Financial Information
6.1.4. Product Portfolio
6.1.5. Recent Developments and Future Outlook

6.2. AstraZeneca
6.2.1. Company Overview
6.2.2. Key Executives
6.2.3. Financial Information
6.2.4. Product Portfolio
6.2.5. Recent Developments and Future Outlook

6.3. Bristol-Myers Squibb
6.3.1. Company Overview
6.3.2. Key Executives
6.3.3. Financial Information
6.3.4. Product Portfolio
6.3.5. Recent Developments and Future Outlook

6.4. Genentech
6.4.1. Company Overview
6.4.2. Key Executives
6.4.3. Product Portfolio
6.4.4. Recent Developments and Future Outlook

6.5. Gilead Sciences
6.5.1. Company Overview
6.5.2. Key Executives
6.5.3. Financial Information
6.5.4. Product Portfolio
6.5.5. Recent Developments and Future Outlook

6.6. GlaxoSmithKline (GSK)
6.6.1. Company Overview
6.6.2. Key Executives
6.6.3. Financial Information
6.6.4. Product Portfolio
6.6.5. Recent Developments and Future Outlook

6.7. Johnson & Johnson
6.7.1. Company Overview
6.7.2. Key Executives
6.7.3. Financial Information
6.7.4. Product Portfolio
6.7.5. Recent Developments and Future Outlook

6.8. Merck
6.8.1. Company Overview
6.8.2. Key Executives
6.8.3. Financial Information
6.8.4. Product Portfolio
6.8.5. Recent Developments and Future Outlook

6.9. Novartis
6.9.1. Company Overview
6.9.2. Key Executives
6.9.3. Financial Information
6.9.4. Product Portfolio
6.9.5. Recent Developments and Future Outlook

6.10. Pfizer
6.10.1. Company Overview
6.10.2. Key Executives
6.10.3. Financial Information
6.10.4. Product Portfolio
6.10.5. Recent Developments and Future Outlook

6.11. Roche
6.11.1. Company Overview
6.11.2. Key Executives
6.11.3. Financial Information
6.11.4. Product Portfolio
6.11.5. Recent Developments and Future Outlook

6.12. ViiV Healthcare
6.12.1. Company Overview
6.12.2. Key Executives
6.12.3. Product Portfolio
6.12.4. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Antiviral Drugs: Partnerships and Collaborations
7.1.1. Analysis by Year of Partnership
7.1.2. Analysis by Type of Partnership
7.1.3. Analysis by Year and Type of Partnership
7.1.4. Analysis by Target Indication
7.1.5. Analysis by Type of Target Virus
7.1.6. Analysis by Type of Partner
7.1.7. Most Active Players: Analysis by Number of Partnerships
7.1.8. Geographical Analysis
7.1.8.1. Intercontinental and Intracontinental Deals 
7.1.8.2. International and Local Deals 

8. FUNDING AND INVESTMENTS
8.1. Antiviral Drugs: Funding and Investments
8.1.1. Analysis by Year of Funding
8.1.2. Analysis of Amount Invested by Year
8.1.3 Analysis by Type of Funding 
8.1.4. Analysis of Amount Invested by Type of Funding 
8.1.5. Analysis by Target Indication 
8.1.6. Analysis by Type of Target Virus
8.1.7. Analysis by Type of Investor
8.1.8. Most Active Players: Analysis by Number of Instances
8.1.9. Most Active Players: Analysis by Amount Invested
8.1.10. Most Active Investors: Analysis by Number of Instances
8.1.11. Geographical Analysis
8.1.11.1. Analysis of Amount Invested by Region
8.1.11.2. Analysis of Amount Invested by Country

9. PORTER’S FIVE FORCES ANALYSIS
9.1. Chapter Overview
9.2. Methodology and Key Parameters
9.3. Porter’s Five Forces
9.3.1. Threat of New Entrants
9.3.2. Bargaining Power of End Users
9.3.3. Bargaining Power of Drug Developers
9.3.4. Threat of Substitute Products 
9.3.5. Rivalry Among Existing Competitors

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Forecast Methodology and Key Assumptions
10.2. Global Antiviral Drugs Market, 2022-2035
10.2.1. Antiviral Drugs Market: Distribution by Mechanism of Action, 2022 and 2035
10.2.1.1. Antiviral Drugs Market for Fusion Inhibitors, 2022-2035
10.2.1.2. Antiviral Drugs Market for DNA Polymerases, 2022-2035
10.2.1.3. Antiviral Drugs Market for Protease Inhibitors, 2022-2035
10.2.1.4. Antiviral Drugs Market for Reverse Transcriptase Inhibitors, 2022-2035
10.2.1.5. Antiviral Drugs Market for Other Mechanisms, 2022-2035

10.2.2. Antiviral Drugs Market: Distribution by Target Indication, 2022 and 2035
10.2.2.1. Antiviral Drugs Market for Human Immunodeficiency Virus Infection, 2022-2035
10.2.2.2. Antiviral Drugs Market for Hepatitis, 2022-2035
10.2.2.3. Antiviral Drugs Market for Coronaviruses Infection, 2022-2035
10.2.2.4. Antiviral Drugs Market for Herpes Simplex Virus Infection, 2022-2035
10.2.2.5. Antiviral Drugs Market for Cytomegalovirus Infection, 2022-2035
10.2.2.6. Antiviral Drugs Market for Influenza, 2022-2035
10.2.2.7. Antiviral Drugs Market for Other Target Indications, 2022-2035

10.2.3. Antiviral Drugs Market: Distribution by Type of Drug Target, 2022 and 2035
10.2.3.1. Antiviral Drugs Market for Virus Targets, 2022-2035
10.2.3.2. Antiviral Drugs Market for Host Targets, 2022-2035

10.2.4. Antiviral Drugs Market: Distribution by Type of Therapy, 2022 and 2035
10.2.4.1. Antiviral Drugs Market for Monotherapy, 2022-2035
10.2.4.2. Antiviral Drugs Market for Combination Therapy, 2022-2035
10.2.5. Antiviral Drugs Market: Distribution by Geography, 2022 and 2035
10.2.5.1. Antiviral Drugs Market in North America, 2022-2035
10.2.5.2. Antiviral Drugs Market in Europe, 2022-2035
10.2.5.3. Antiviral Drugs Market in Asia-Pacific, 2022-2035
10.2.5.4. Antiviral Drugs Market in Latin America, 2022-2035
10.2.5.5. Antiviral Drugs Market in MENA, 2022-2035
10.2.5.6. Antiviral Drugs Market in Rest of the World, 2022-2035

11. EXECUTIVE INSIGHTS
11.1. Chapter Overview
11.2. Pardes Biosciences
11.2.1. Company Snapshot
11.2.2. Interview Transcript: Sean Brusky, Chief Commercial Officer

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape of Approved Antiviral Drugs
Figure 2.2 Executive Summary: Overall Market Landscape of Clinical-stage Antiviral Drugs
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investments
Figure 2.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Types of Viruses
Figure 3.2 Mechanism of Action of Antiviral Drugs
Figure 4.1 Approved Antiviral Drugs: Distribution by Year of Approval
Figure 4.2 Approved Antiviral Drugs: Distribution by Type of Dosage Form
Figure 4.3 Approved Antiviral Drugs: Distribution by Type of Molecule
Figure 4.4 Approved Antiviral Drugs: Distribution by Type of Target Virus
Figure 4.5 Approved Antiviral Drugs: Distribution by Route of Administration
Figure 4.6 Approved Antiviral Drugs: Distribution by Dosing Frequency
Figure 4.7 Approved Antiviral Drugs: Distribution by Target Indication
Figure 4.8 Approved Antiviral Drugs: Distribution by Mechanism of Action
Figure 4.9 Approved Antiviral Drugs Developers: Distribution by Year of Establishment
Figure 4.10 Approved Antiviral Drugs Developers: Distribution by Company Size
Figure 4.11 Approved Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Figure 4.12 Approved Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Figure 4.13 Most Active Players: Distribution by Number of Approved Drugs
Figure 5.1 Clinical Antiviral Drugs: Distribution by Phase of Development
Figure 5.2 Clinical Antiviral Drugs: Distribution by Type of Molecule
Figure 5.3 Clinical Antiviral Drugs: Distribution by Phase of Development and Type of Molecule
Figure 5.4 Clinical Antiviral Drugs: Distribution by Type of Dosage Form
Figure 5.5 Clinical Antiviral Drugs: Distribution by Route of Administration
Figure 5.6 Clinical Antiviral Drugs: Distribution by Target Indication
Figure 5.7 Clinical Antiviral Drugs: Distribution by Phase of Development and Target Indication
Figure 5.8 Clinical Antiviral Drugs: Distribution by Type of Developer
Figure 5.9 Clinical Antiviral Drugs: Distribution by Type of Therapy
Figure 5.10 Clinical Antiviral Drugs: Distribution by Target Patient Segment
Figure 5.11 Clinical Antiviral Drugs: Distribution by Mechanism of Action
Figure 5.12 Clinical Antiviral Drugs: Distribution by Type of Target Virus
Figure 5.13 Clinical Antiviral Drugs: Distribution by Number of Doses
Figure 5.14 Clinical Antiviral Drugs Developers: Distribution by Year of Establishment
Figure 5.15 Clinical Antiviral Drugs Developers: Distribution by Company Size
Figure 5.16 Clinical Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Figure 5.17 Clinical Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Figure 5.18 Clinical Antiviral Drugs Developers: Distribution by Company Size and Location of Headquarters
Figure 5.19 Most Active Players: Distribution by Number of Clinical-Stage Drugs
Figure 7.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Target Indication
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Target Virus
Figure 7.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.7 Most Active Players: Distribution by Number of Partnerships
Figure 7.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 7.9 Partnerships and Collaborations: International and Local Deals
Figure 8.1 Funding and Investments: Distribution by Year of Funding
Figure 8.2 Funding and Investments: Distribution of Amount Invested by Year
Figure 8.3 Funding and Investments: Distribution by Type of Funding
Figure 8.4 Funding and Investments: Distribution of Amount Invested by Type of Funding
Figure 8.5 Funding and Investments: Distribution by Target Indication
Figure 8.6 Funding and Investments: Distribution by Type of Target Virus
Figure 8.7 Funding and Investments: Distribution by Type of Investor
Figure 8.8 Most Active Players: Distribution by Number of Instances
Figure 8.9 Most Active Players: Distribution by Amount Invested
Figure 8.10 Most Active Investors: Distribution by Number of Instances
Figure 8.11 Funding and Investments: Distribution of Amount Invested by Region
Figure 8.12 Funding and Investments: Distribution of Amount Invested by Country
Figure 9.1 Antiviral Drugs: Porter’s Five Forces Analysis
Figure 10.1 Global Antiviral Drugs Market, 2022-2035 (USD Billion)
Figure 10.2 Antiviral Drugs Market: Distribution by Mechanism of Action, 2022 and 2035 (USD Billion)
Figure 10.3 Antiviral Drugs Market for Fusion Inhibitors, 2022-2035 (USD Billion)
Figure 10.4 Antiviral Drugs Market for DNA Polymerases, 2022-2035 (USD Billion)
Figure 10.5 Antiviral Drugs Market for Protease Inhibitors, 2022-2035 (USD Billion)
Figure 10.6 Antiviral Drugs Market for Reverse Transcriptase Inhibitors, 2022-2035 (USD Billion)
Figure 10.7 Antiviral Drugs Market for Other Mechanisms, 2022-2035 (USD Billion)
Figure 10.8 Antiviral Drugs Market: Distribution by Target Indication, 2022 and 2035 (USD Billion)
Figure 10.9 Antiviral Drugs Market for Human Immunodeficiency Virus Infection, 2022-2035 (USD Billion)
Figure 10.10 Antiviral Drugs Market for Hepatitis, 2022-2035 (USD Billion)
Figure 10.11 Antiviral Drugs Market for Coronavirus Infection, 2022-2035 (USD Billion)
Figure 10.12 Antiviral Drugs Market for Herpes Simplex Virus Infection, 2022-2035 (USD Billion)
Figure 10.13 Antiviral Drugs Market for Cytomegalovirus Infection, 2022-2035 (USD Billion)
Figure 10.14 Antiviral Drugs Market for Influenza, 2022-2035 (USD Billion)
Figure 10.15 Antiviral Drugs Market for Other Target Indications, 2022-2035 (USD Billion)
Figure 10.16 Antiviral Drugs Market: Distribution by Type of Drug Target, 2022 and 2035 (USD Billion)
Figure 10.17 Antiviral Drugs Market for Virus Targets, 2022-2035 (USD Billion)
Figure 10.18 Antiviral Drugs Market for Host Targets, 2022-2035 (USD Billion)
Figure 10.19 Antiviral Drugs Market: Distribution by Type of Therapy, 2022 and 2035 (USD Billion)
Figure 10.20 Antiviral Drugs Market for Monotherapy, 2022-2035 (USD Billion)
Figure 10.21 Antiviral Drugs Market for Combination Therapy, 2022-2035 (USD Billion)
Figure 10.22 Antiviral Drugs Market: Distribution by Geography, 2022 and 2035 (USD Billion)
Figure 10.23 Antiviral Drugs Market in North America, 2022-2035 (USD Billion)
Figure 10.24 Antiviral Drugs Market in Europe, 2022-2035 (USD Billion)
Figure 10.25 Antiviral Drugs Market in Asia-Pacific, 2022-2035 (USD Billion)
Figure 10.26 Antiviral Drugs Market in Latin America, 2022-2035 (USD Billion)
Figure 10.27 Antiviral Drugs Market in MENA, 2022-2035 (USD Billion)
Figure 10.28 Antiviral Drugs Market in Rest of the World, 2022-2035 (USD Billion)

List Of Tables

Table 4.1 List of Approved Antiviral Drugs
Table 4.2 List of Approved Antiviral Drug Developers
Table 5.1 List of Clinical-Stage Antiviral Drugs
Table 5.2 List of Clinical-Stage Antiviral Drug Developers
Table 6.1 AbbVie: Product Portfolio
Table 6.2 AbbVie: Recent Developments and Future Outlook
Table 6.3 AstraZeneca: Product Portfolio
Table 6.4 AstraZeneca: Recent Developments and Future Outlook
Table 6.5 Bristol-Myers Squibb: Product Portfolio
Table 6.6 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 6.7 Genentech: Product Portfolio
Table 6.8 Genentech: Recent Developments and Future Outlook
Table 6.9 Gilead Sciences: Product Portfolio
Table 6.10 Gilead Sciences: Recent Developments and Future Outlook
Table 6.11 GlaxoSmithKline: Product Portfolio
Table 6.12 GlaxoSmithKline: Recent Developments and Future Outlook
Table 6.13 Johnson & Johnson: Product Portfolio
Table 6.14 Johnson & Johnson: Recent Developments and Future Outlook
Table 6.15 Merck: Product Portfolio
Table 6.16 Merck: Recent Developments and Future Outlook
Table 6.17 Novartis: Product Portfolio
Table 6.18 Novartis: Recent Developments and Future Outlook
Table 6.19 Pfizer: Product Portfolio
Table 6.20 Pfizer: Recent Developments and Future Outlook
Table 6.21 Roche: Product Portfolio
Table 6.22 Roche: Recent Developments and Future Outlook
Table 6.23 ViiV Healthcare: Product Portfolio
Table 6.24 ViiV Healthcare: Recent Developments and Future Outlook
Table 7.1 Antiviral Drugs: List of Partnerships and Collaborations
Table 8.1 Antiviral Drugs: List of Funding and Investments
Table 12.1 Approved Antiviral Drugs: Distribution by Year of Approval
Table 12.2 Approved Antiviral Drugs: Distribution by Type of Dosage Form
Table 12.3 Approved Antiviral Drugs: Distribution by Type of Molecule
Table 12.4 Approved Antiviral Drugs: Distribution by Type of Target Virus
Table 12.5 Approved Antiviral Drugs: Distribution by Route of Administration
Table 12.6 Approved Antiviral Drugs: Distribution by Dosing Frequency
Table 12.7 Approved Antiviral Drugs: Distribution by Target Indication
Table 12.8 Approved Antiviral Drugs: Distribution by Mechanism of Action
Table 12.9 Approved Antiviral Drugs Developers: Distribution by Year of Establishment
Table 12.10 Approved Antiviral Drugs Developers: Distribution by Company Size
Table 12.11 Approved Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Table 12.12 Approved Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Table 12.13 Most Active Players: Distribution by Number of Approved Drugs
Table 12.14 Clinical Antiviral Drugs: Distribution by Phase of Development
Table 12.15 Clinical Antiviral Drugs: Distribution by Type of Molecule
Table 12.16 Clinical Antiviral Drugs: Distribution by Phase of Development and Type of Molecule
Table 12.17 Clinical Antiviral Drugs: Distribution by Type of Dosage Form
Table 12.18 Clinical Antiviral Drugs: Distribution by Route of Administration
Table 12.19 Clinical Antiviral Drugs: Distribution by Target Indication
Table 12.20 Clinical Antiviral Drugs: Distribution by Phase of Development and Target Indication
Table 12.21 Clinical Antiviral Drugs: Distribution by Type of Developer
Table 12.22 Clinical Antiviral Drugs: Distribution by Type of Therapy
Table 12.23 Clinical Antiviral Drugs: Distribution by Target Patient Segment
Table 12.24 Clinical Antiviral Drugs: Distribution by Mechanism of Action
Table 12.25 Clinical Antiviral Drugs: Distribution by Type of Target Virus
Table 12.26 Clinical Antiviral Drugs: Distribution by Number of Doses
Table 12.27 Clinical Antiviral Drugs Developers: Distribution by Year of Establishment
Table 12.28 Clinical Antiviral Drugs Developers: Distribution by Company Size
Table 12.29 Clinical Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Table 12.30 Clinical Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Table 12.31 Clinical Antiviral Drugs Developers: Distribution by Company Size and Location of Headquarters
Table 12.32 Most Active Players: Distribution by Number of Clinical-stage Drugs
Table 12.33 Partnerships and Collaborations: Distribution by Year of Partnership
Table 12.34 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.35 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 12.36 Partnerships and Collaborations: Distribution by Target Indication
Table 12.37 Partnerships and Collaborations: Distribution by Type of Target Virus
Table 12.38 Partnerships and Collaborations: Distribution by Type of Partner
Table 12.39 Most Active Players: Distribution by Number of Partnerships
Table 12.40 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 12.41 Partnerships and Collaborations: International and Local Deals
Table 12.42 Funding and Investments: Distribution by Year of Funding
Table 12.43 Funding and Investments: Distribution of Amount Invested by Year
Table 12.44 Funding and Investments: Distribution of by Type of Fundings
Table 12.45 Funding and Investments: Distribution of Amount Invested by Type of Funding
Table 12.46 Funding and Investments: Distribution by Target Indication
Table 12.47 Funding and Investments: Distribution by Type of Target Virus
Table 12.48 Funding and Investments: Distribution by Type of Investor
Table 12.49 Most Active Players: Distribution by Number of Instances
Table 12.50 Most Active Players: Distribution by Amount Invested
Table 12.51 Most Active Investors: Distribution by Number of Instances
Table 12.52 Funding and Investments: Distribution of Amount Invested by Region
Table 12.53 Funding and Investments: Distribution of Amount Invested by Country
Table 12.54 Global Antiviral Drugs Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.55 Antiviral Drugs Market: Distribution by Mechanism of Action, 2022 and 2035 (USD Billion)
Table 12.56 Antiviral Drugs Market for Fusion Inhibitors, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.57 Antiviral Drugs Market for DNA Polymerases, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.58 Antiviral Drugs Market for Protease Inhibitors, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.59 Antiviral Drugs Market for Reverse Transcriptase Inhibitors, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.60 Antiviral Drugs Market for Other Mechanisms, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.61 Antiviral Drugs Market: Distribution by Target Indication, 2022 and 2035 (USD Billion)
Table 12.62 Antiviral Drugs Market for Human Immunodeficiency Virus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.63 Antiviral Drugs Market for Hepatitis, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.64 Antiviral Drugs Market for Coronavirus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.65 Antiviral Drugs Market for Herpes Simplex Virus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.66 Antiviral Drugs Market for Cytomegalovirus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.67 Antiviral Drugs Market for Influenza, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.68 Antiviral Drugs Market for Other Target Indications, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.69 Antiviral Drugs Market: Distribution by Type of Drug Target, 2022 and 2035 (USD Billion)
Table 12.70 Antiviral Drugs Market for Virus Targets, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.71 Antiviral Drugs Market for Host Targets, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.72 Antiviral Drugs Market: Distribution by Type of Therapy, 2022 and 2035 (USD Billion)
Table 12.73 Antiviral Drugs Market for Monotherapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.74 Antiviral Drugs Market for Combination Therapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.75 Antiviral Drugs Market: Distribution by Geography, 2022 and 2035 (USD Billion)
Table 12.76 Antiviral Drugs Market in North America, 2022-2035 (USD Billion)
Table 12.77 Antiviral Drugs Market in Europe, 2022-2035 (USD Billion)
Table 12.78 Antiviral Drugs Market in Asia-Pacific, 2022-2035 (USD Billion)
Table 12.79 Antiviral Drugs Market in Latin America, 2022-2035 (USD Billion)
Table 12.80 Antiviral Drugs Market in MENA, 2022-2035 (USD Billion)
Table 12.81 Antiviral Drugs Market in Rest of the World, 2022-2035 (USD Billion)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. 101 Therapeutics
2. 30 TECHNOLOGY
3. 3M
4. 60 Degrees Pharmaceuticals (60P)
5. Aardvark Therapeutics
6. Aarhus University Hospital
7. AB Science
8. AbbVie
9. AbCellera
10. Abderrahmane Mami Hospital
11. Acerta Pharma
12. Acticor Biotech
13. Adage Capital Management
14. Adagio Therapeutics
15. Adamis Pharmaceuticals
16. Adimab
17. Adjuvant Capital
18. Advagene Biopharma
19. Aevi Genomic Medicine (acquired by Avalo Therapeutics)
20. Afyonkarahisar Health Sciences University
21. AGC Biologics
22. AgelessRx
23. AiPharma
24. Airway Therapeutics
25. Aisling Capital
26. Ajinomoto Bio-Pharma Services
27. Albatross Capital
28. Aldeyra Therapeutics
29. Alexandria Venture Investments
30. Algernon Pharmaceuticals
31. Aligos Therapeutics
32. AlloVir
33. Ally Bridge Group
34. Alnylam Pharmaceuticals
35. Alphamab
36. Altium Capital
37. Altum Pharmaceuticals (subsidiary of BetterLife's)
38. Amarex Clinical Research
39. American Gene Technologies International
40. amfAR
41. Amgen
42. Ampio Pharmaceuticals
43. Amplyx Pharmaceuticals
44. Amsterdam UMC
45. Amyndas Pharmaceuticals
46. Amzak Health
47. ANA Therapeutics (acquired by NeuroBo Pharmaceuticals)
48. Anaxago
49. Andera Partners
50. Angel Pharmaceuticals
51. ANRS
52. Ansun Biopharma
53. Antios Therapeutics
54. Antiva Biosciences
55. Anzu Partners
56. APCER Life Sciences
57. APEIRON Biologics
58. Apellis Pharmaceuticals
59. Apex Services
60. APICES
61. Appili Therapeutics
62. Applied Biology
63. AptaBio Therapeutics
64. Arbutus Biopharma
65. ARCA Biopharma
66. Ark Biosciences
67. Arrowhead Pharmaceuticals
68. ArrowMark Partners
69. ARTIS Ventures
70. Ascletis Pharma
71. Ashfield Engage
72. Ashvattha Therapeutics
73. Aspire Capital Fund
74. Assembly Biosciences
75. Assistance Publique - Hôpitaux de Paris
76. AstraZeneca
77. Atea Pharmaceuticals
78. Atreca
79. Atriva Therapeutics
80. aTyr Pharma
81. Austria Wirtschaftsservice Gesellschaft (aws)
82. Austrian Research Promotion Agency (FFG)
83. Avantor
84. Avego BioScience Capital (formerly known as Google Ventures)
85. Avestria Ventures
86. Avid Bioservices
87. Azidus Brasil
88. AzurRx BioPharma
89. Bain Capital Life Sciences
90. Banque Populaire
91. Bausch + Lomb
92. Bausch Health
93. Bayer
94. Baylor College of Medicine
95. BDgene
96. BDR Pharmaceuticals
97. Beech Tree Labs
98. BeiGene
99. Beijing Defengrei Biotechnology
100. Beijing Genova Biotech
101. Beijing Tiantan Biological Products
102. BerGenBio
103. Beximco Pharmaceuticals
104. Bharat Serums and Vaccines
105. Bill & Melinda Gates Foundation
106. Bill & Melinda Gates Medical Research Institute
107. BioAge Labs
108. BioAgilytix
109. BIOCAD
110. Bioclinica
111. Biocon Biologics
112. BioCryst Pharmaceuticals
113. Biogen
114. Biohaven Pharmaceuticals
115. Biomedical Advanced Research and Development Authority (BARDA)
116. Bionorica
117. Biorasi
118. Biotest
119. Blade Therapeutics
120. BlueSky Immunotherapies
121. BNC Korea
122. BNK Venture Capital
123. Boan Biotech (a subsidiary of Luye Pharma Group)
124. Boehringer Ingelheim
125. Boxer Capital
126. Bpifrance
127. Brace Pharma Capital
128. Brigham and Women's Hospital
129. Brii Biosciences
130. Bristol-Myers Squibb
131. BronxCare Health System
132. Bukwang Pharmaceutical
133. Cadila Healthcare
134. California Institute for Regenerative Medicine (CIRM)
135. CAM Capital
136. Cambridge Innovation Capital
137. Canaan Partners
138. Cancer Research Institute
139. Can-Fite BioPharma
140. Cardresearch
141. Carelink Pharmaceutical
142. Cascade Chemistry
143. Celgene
144. Celltrion
145. Celonic
146. Celularity
147. Cenduit
148. Cenexi
149. Center for Drug Evaluation (CDE), Taiwan
150. Chemical Diversity Research Institute
151. Chime Biologics
152. China Immunotech (Beijing) Biotechnology
153. China Meheco
154. China National Biotec Group
155. China Venture Capital Fund
156. Chinese Academy of Medical Sciences
157. Chong Kun Dang Pharmaceutical
158. CHRISTUS Health
159. Chromis
160. CICC Qide
161. Cipla
162. Clear Creek Bio
163. Clearpool https://www.zoominfo.com/c/clinedem/532452984
164. Clene Nanomedicine
165. Clinedem
166. CLINICAL RESEARCH VIET NAM SKILL TRAINING AND CONSULTING
167. Clinical Service Center
168. Clinical Trial Consultants
169. Clinigen
170. Clinipace
171. Cocrystal Pharma
172. Code Pharma
173. Colorado Prevention Center
174. Columbia University
175. Copycat Sciences
176. CORAT Therapeutics
177. Cormorant Asset Management
178. Coronavirus Immunotherapy Consortium (CoVIC)
179. Corpometria Institute
180. Corvus Pharmaceuticals
181. Cosmo Pharmaceuticals
182. Cota Capital
183. CR Double-Crane
184. CR-CP Life Science Fund
185. Cromos Pharma
186. CSL Behring
187. CTI Clinical Trial and Consulting Services
188. Cue Biopharma
189. Curavit Clinical Research
190. CytoDyn
191. Daewoong Pharmaceuticals
192. DalCor Pharmaceuticals
193. DataMap
194. Datametrix
195. DCVC Bio
196. Debiopharm
197. Defense Advanced Research Projects Agency (DARPA)
198. Defense Health Agency (DHA)
199. Definvest
200. Delos Capital
201. Department of Health and Human Services
202. Dermapharm
203. Dicerna Pharmaceuticals
204. dievini Hopp Biotech
205. Diffusion Pharmaceuticals
206. Domain Associates
207. Dompé
208. Dong-A ST
209. Dongguan HEC TaiGen Biopharmaceuticals
210. Door Pharmaceuticals
211. Dr. Reddy’s Laboratories
212. DSG
213. Duke-NUS Medical School
214. ECOGENE-21
215. Edesa Biotech
216. eFFECTOR Therapeutics
217. EIC Fund
218. Eiger BioPharmaceuticals
219. Elaia
220. Eli Lilly
221. ELPEN
222. EMD Serono
223. Emergent BioSolutions
224. Emergo Therapeutics
225. Emory University
226. EmphyCorp
227. Enanta Pharmaceuticals
228. ENYO Pharma
229. EOM Pharmaceuticals
230. Epiq Capital
231. EQRx
232. Equilab International
233. Erasmus University Medical Center
234. Erste Bank
235. Eshmoun-Clinical Research
236. Etana Biotechnologies
237. Eunice Kennedy Shriver National Institute of Child Health and Human
238. European Commission
239. European Investment Bank
240. European Union
241. Everest Medicines
242. Everest Venture Capital
243. Evergreen Therapeutics
244. Evive Biotech
245. Excision BioTherapeutics
246. Exvastat
247. Eye & ENT Hospital of Fudan University
248. Fab'entech
249. Family First Medical Research Center
250. Farmak
251. Farmoquímica
252. Federal Budget Institution of Science
253. Central Research Institute of Epidemiology of Rospotrebnadzor
254. Federal Government of Switzerland
255. Federated Hermes
256. FengChuan capital
257. FHI Clinical
258. Fidelity Management & Research
259. First Light Asset Management
260. First Wave BioPharma
261. Flanders Innovation & Entrepreneurship
262. Florence Healthcare
263. Foresite Capital
264. Forest Pharmaceuticals
265. Fosun Pharma
266. Founders Fund
267. Fraunhofer Institute for Molecular Biology and Applied Ecology
268. Community Regional Medical Center
269. Frontier Biotechnologies
270. Fujian Cosunter Pharmaceutical
271. FUJIFILM Diosynth Biotechnologies
272. FUJIFILM Pharmaceuticals
273. FUJIFILM Toyama Chemical
274. Gaingels
275. Genentech
276. Generation Bio
277. Genexine
278. Genoscience Pharma
279. George Clinical
280. German Federal Ministry of Education and Research
281. Federal Ministry of Health (Germany)
282. Ghent University Hospital
283. Ghost Tree Capital
284. GIC
285. Gilead Sciences
286. Global Response Aid (GRA)
287. Golden Biotechnology
288. GordonMD Global Investments
289. Gorgas Memorial Institute for Health Studies (GMI)
290. Government of Canada
291. Government of France
292. Grand Medical
293. Granite Point Capital Management
294. GreatPoint Ventures
295. Green Sands Equity
296. Grifols Therapeutics
297. GSK
298. Guangzhou Henovcom Bioscience
299. Guangzhou Lupeng Pharmaceutical
300. GV
301. Halozyme Therapeutics
302. Hamad Medical
303. Hankang Capital
304. Harbour BioMed
305. HBM Healthcare Investments
306. HealthCor Management
307. Heartland Healthcare Capital
308. Hebei Yanda Ludaopei Hospital
309. Heidelberg ImmunoTherapeutics
310. Heilongjiang ZBD Pharmaceutical
311. HeNan Sincere Biotech
312. Hengenix Biotech
313. Hengxu Capital
314. Hepion Pharmaceuticals
315. HiFiBiO Therapeutics
316. High-Tech Gründerfonds (HTGF)
317. Hinova Pharmaceuticals
318. HitGen
319. Hongtao Capital
320. HOOKIPA Pharma
321. Hospital Alemão Oswaldo Cruz
322. Hospital Casa de Saúde
323. Hospital do Coração
324. Hospital Israelita Albert Einstein
325. Hospital Moinhos de Vento
326. Hospital Santo Tomás
327. Huadong Medicine
328. Huahui Health
329. Humanigen
330. Huoshenshan Hospital
331. hVIVO
332. ICLPharma
333. ICON
334. IGM Biosciences
335. ILTOO Pharma
336. I-Mab Biopharma
337. Immune Biosolutions
338. Immune System Regulation (ISR)
339. Immunic
340. ImmunityBio
341. ImmunoCellular Therapeutics
342. Imuneks Farma
343. Incepta Pharmaceuticals
344. Incozen
345. Incyte
346. IndusAge Partners
347. Infectious Disease Research Institute (IDRI)
348. InnoStar Solutions
349. Innovation Pharmaceuticals
350. Innovent Biologics
351. Inotrem
352. Inova Health System
353. Instat Clinical Research
354. Institut Mérieux
355. Institut Pasteur Korea
356. International Maternal Pediatric Adolescent AIDS Clinical Trials Network
357. InterX
358. Invesco Developing Markets Fund
359. Invus
360. Ionis Pharmaceuticals
361. IQVIA
362. Israeli Ministry of Health (MoH)
363. J.P. Morgan Securities
364. Janssen
365. Janus Henderson Investors
366. Japan Agency for Medical Research and Development
367. Jazz Pharmaceuticals
368. Jena University Hospital
369. Jiangsu Famaison Medical Technology
370. Jiangsu Hansoh Pharmaceutical
371. Jiangsu Hengrui Pharmaceuticals
372. Jiangsu Pacific Meinuoke Bio-pharmaceutical
373. Johns Hopkins University
374. Johnson & Johnson
375. JSS Medical Research
376. Junshi Biosciences
377. JX Partners
378. KABS Laboratories
379. Kamada
380. Kansas State University
381. Karyopharm Therapeutics
382. Kedrion Biopharma
383. KGbio
384. Kinevant Sciences
385. King Pharmaceuticals
386. Kiniksa Pharmaceuticals
387. Kintor Pharmaceutical
388. Kite Pharma
389. Korea Institute of Radiological & Medical Sciences
390. Korea United Pharm
391. Kowa
392. KPM Tech
393. Kreaxi
394. KResearch
395. KU Leuven
396. Kukbo
397. Kyorin Pharmaceutical
398. Kyowa Kirin
399. Kyushu University
400. LabCorp Drug Development
401. Labo'Life
402. Laboratoire Boréaderme
403. Laboratorios Silanes
404. Lake Bleu Capital
405. Laurent Pharma
406. Leidos
407. Lewis Katz School of Medicine
408. LFB
409. LianBio
410. LifeSci Venture Partners
411. Ligand Pharmaceuticals
412. Light Chain Bioscience
413. Lilly Asia Ventures (LAV)
414. Lind Global Fund II
415. Linear Clinical Research
416. List Biological Laboratories
417. Logos Capital
418. Loreda Holdings
419. Lumira Ventures
420. Lung Biotechnology
421. Lupin
422. Luxna Biotech
423. Luye Pharma
424. M.D. Anderson Cancer Center
425. M28 Capital
426. mAbxience
427. MacroGenics
428. Shenzhen Maiwei BioTech
429. Malakoff Humanis
430. Mana Ventures
431. Massachusetts General Hospital
432. Matrix Partners China
433. Mayo Clinic
434. Athens Medical Society
435. Medical University of Silesia
436. Medical University of Vienna
437. MediciNova
438. MedImmune
439. Medpace
440. MedRegen
441. Memorial Sloan Kettering Cancer Center
442. Meneldor
443. Merck
444. Merck KGaA
445. Merck Sharp & Dohme
446. Mereo BioPharma
447. MetrioPharm
448. Metro International Biotech
449. Ministry of Health (Morocco)
450. MiNK Therapeutics
451. Missouri State University
452. Mithril
453. ModeX Therapeutics
454. Molecular Partners
455. Institut de recherches cliniques de Montréal (IRCM)
456. Moorim Capital
457. Morningside Ventures
458. Mount Sinai Health System
459. Mylan
460. Nabuboto
461. Nanjing Sanhome Pharmaceutical
462. NantKwest
463. National Cancer Institute (NCI)
464. National Center for Advancing Translational Sciences (NCATS)
465. National Center for Global Health and Medicine
466. National Heart, Lung, and Blood Institute (NHLBI)
467. National Institute of Allergy and Infectious Diseases (NIAID)
468. National Institute of Mental Health (NIMH)
469. National Institute on Deafness and Other Communication Disorders (NIDCD)
470. National Institutes of Health (NIH)
471. National Research Council of Canada Industrial Research Assistance Program
472. National University Hospital, Singapore
473. National University of Singapore
474. Natural Capital Investment Fund
475. Naval Medical Research Unit 3 (NAMRU-3)
476. Navigen
477. NBank Capital
478. NEAT ID Foundation
479. Nektar Therapeutics
480. NeoImmuneTech
481. Neurelis
482. NeuroActiva
483. NeuroBo Pharmaceuticals
484. NeuroRx
485. NeuTec Pharma (acquired by Novartis)
486. Neutrolis
487. New Leaf Venture Partners
488. Newsoara BioPharma
489. NiKang Therapeutics
490. Nobelpharma
491. Noblewell
492. Noorik Biopharmaceuticals
493. Norwest Venture Partners
494. Norwich Clinical Research Associates
495. Nova Healthcare
496. Novartis
497. Novatek Pharmaceuticals
498. Novo Holdings
499. Nucorion Pharmaceuticals
500. OBCTCD24
501. Ohara Pharmaceutical
502. Oklahoma State University
503. Olatec Therapeutics
504. Olive Tree Capital
505. Omega Funds
506. OncoImmune (acquired by Merck)
507. Opera
508. Ophirex
509. OPKO Health
510. OrbiMed
511. OrbiMed Advisors
512. Organicell Regenerative Medicine
513. Osage University Partners
514. Paidion Research (acquired by Premier Research)
515. Palo Alto Pharmaceuticals
516. Pardes Biosciences
517. Partner Therapeutics
518. PDS Biotechnology
519. Peking University First Hospital
520. Perceptive Advisors
521. Petrovax
522. Pfizer
523. Pharco Pharmaceuticals
524. Pharma Holdings
525. Pharma Nord
526. Pharmaceutical Solutions
527. PharmaEssentia
528. PharmaMar
529. Pharmascience
530. PHARMENTERPRISES
531. Pharm-Olam
532. Pharmsynthez
533. Pivotal bioVenture Partners
534. Plum Alley Investments
535. Polaris Partners
536. Polish Medical Research Agency (ABM)
537. Pontifax
538. Pontificia Universidad Católica de Chile
539. Population Health Partners
540. Population Health Research Institute (PHRI)
541. POSCO Capital
542. PPD
543. Premji Invest
544. Presight Capital
545. PRISM BioLab
546. Proteros Biostructures
547. Prothione
548. Proxima Clinical Research
549. PT Lloyd Pharma
550. PTC Therapeutics
551. Pulmoquine Therapeutics
552. Pulmotect
553. Pulthera
554. PureTech Health
555. Q2 Solutions
556. QbD Clinical
557. Qilu Pharmaceutical
558. Jiangxi Qingfeng Pharmaceutical
559. Quercis Pharma
560. R&G PharmaStudies
561. RA Capital Management
562. Rabin Medical Center
563. Radboud University Medical Center
564. Rawalpindi Medical University
565. Guangdong Raynovent Biotech
566. RedHill Biopharma
567. Redmile Group
568. Regeneron Pharmaceuticals
569. Resolve Therapeutics
570. Resverlogix
571. Retrograde Investments
572. RetroLead (Shanghai) BioPharma
573. Reven Pharmaceuticals
574. RevImmune
575. ReViral (acquired by Pfizer)
576. Revive Therapeutics
577. Rhizen Pharmaceuticals
578. Ride Wave Ventures
579. Ridgeback Biotherapeutics
580. Rigel Pharmaceuticals
581. Roche
582. Rock Springs Capital
583. Rockefeller University
584. Laboratorios Roemmers
585. Roivant Sciences
586. Romark
587. R-Pharm
588. RQ Biotechnology
589. Ruijin Hospital
590. Russian Academy of Medical Sciences
591. SAB Biotherapeutics
592. Sagent Pharmaceuticals
593. Saigon Biopharma
594. Saint Luke’s Mid America Heart Institute
595. Samel
596. Samsara BioCapital
597. Samsung BioLogics
598. Sanofi
599. Sao Thai Duong Joint Stock Company
600. SCiAN Services
601. Scientific Center for Anti-infectious Drugs
602. Sciwind Biosciences
603. Scotmann Pharmaceuticals
604. Scripps Research
605. Sectoral Asset Management
606. Selva Therapeutics
607. Senhwa Biosciences
608. Seoul Investment Partners
609. SGS
610. Shanghai East Hospital
611. Shanghai Free Trade Zone Equity Investment Fund
612. Shanghai Hepu Pharmaceutical
613. Shanghai Pharmaceuticals
614. Shanghai Tongren Hospital
615. Shanxi Kangbao Biological Product
616. Shaperon
617. Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry (IBCh)
618. Shenyang Tonglian Pharmaceutical
619. Shenzhen Co-way Capital Services
620. Shenzhen Share Capital
621. Shin Poong Pharma
622. Shionogi
623. SIGA Technologies
624. Sigma Gestion
625. SigmaDrugs
626. Simbec-Orion
627. Singapore Clinical Research Institute (SCRI)
628. Singlomics Biopharmaceuticals
629. Sinopharm
630. Sinopharm-CICC Capital
631. Sirona Capital
632. Sironax
633. Sixty Degree Capital
634. SmartPharm Therapeutics
635. Smilegate Investment
636. SOCAR Research
637. Societe Generale
638. Sofinnova Ventures
639. Soleus Capital
640. SomaLogic
641. Soroka Medical Center
642. Sorrento Therapeutics
643. Sound Pharmaceuticals
644. South Dakota Equity Partners
645. Staidson Biopharma
646. Statera Biopharma
647. Stemedica Cell Technologies
648. Sun Pharma
649. Sunshine Lake Pharma (a subsidiary of HEC Pharm)
650. SuperGene
651. Supriya LifeScience
652. Surveyor Capital
653. Swiss National Science Foundation (SNSF)
654. Synairgen
655. Syneos Health
656. TaiGen Biotechnology
657. TaiMed Biologics
658. TaiwanJ Pharmaceuticals
659. Takeda Pharmaceuticals
660. Telcon RF Pharmaceutical
661. Telios Pharma
662. Temasek
663. The Medicines Patent Pool (MPP)
664. The Montreal Health Innovations Coordinating Center (MHICC)
665. The Supreme Council for the Arab-African Economy
666. The Vienna Business Agency
667. Theravance Biopharma
668. Thermo Fisher Scientific
669. Third People's Hospital of Shenzhen
670. Thrombosis Research Institute
671. Tiantu Capital
672. TLC BioSciences
673. Tokyo Metropolitan Komagome Hospital
674. Tokyo Shinagawa Hospital
675. Toscana Life Sciences
676. Transcenta
677. Tribe Capital
678. Trinity Health
679. TSB Therapeutics
680. Tsinghua University
681. Turn Therapeutics
682. Turnstone Biologics
683. Tychan
684. U.S. Department of Defense
685. U.S. Department of Health and Human Services (HHS)
686. UCB Pharma
687. United BioPharma
688. United Medical Specialties
689. United Nations Children’s Fund (UNICEF)
690. United States Department of Defense
691. UnitedHealth Group
692. University Hospital, Basel, Switzerland
693. Institut Universitaire de Cardiologie et de Pneumologie de Québec
694. University Medical Center Goettingen
695. University Medical Center of Johannes Gutenberg University Mainz
696. University of Aarhus
697. University of Alabama at Birmingham
698. University of Arizona
699. University of California
700. University of Chicago
701. University of Cologne
702. University of Michigan
703. University of Minnesota
704. University of Nairobi
705. University of Nebraska
706. University of Oxford
707. University of Pennsylvania
708. University of Utah
709. US Biotest
710. US Government
711. Utrecht University
712. Valeant Pharmaceuticals (now Bausch Health)
713. Valenta Pharm
714. Valiant Capital Partners
715. Vanderbilt University Medical Center
716. Vasomune Therapeutics
717. VBL Therapeutics
718. Venrock Healthcare Capital Partners
719. Veranex
720. Verastem Oncology
721. Verrica Pharmaceuticals
722. Veru
723. VetStem Biopharma
724. Via Christi Research
725. Vienna Insurance Group (VIG)
726. Vietstar Biomedical Research
727. Vigonvita Life Sciences
728. ViiV Healthcare
729. Viking Global Investors
730. Vir Biotechnology
731. ViralClear
732. Viriom
733. VirTrial
734. Visterra
735. Hainan Visum Pharmaceutical (acquired by TWi Pharmaceuticals)
736. Wellington Management Company
737. Westat
738. Windtree Therapeutics
739. WRVI Capital
740. X-Chem
741. XENOTHERA
742. Xi'an Xintong Pharmaceutical Research
743. Yuanta Investment
744. Zhejiang Hisun Pharmaceutical

Source 1: https://www.thelancet.com/article/S0140-6736(21)02796-3/fulltext